Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Terence H W Ching, Lucia Amoroso, Calvin Bohner, Elizabeth D'Amico, Jeffrey Eilbott, Tara Entezar, Madison Fitzpatrick, Geena Fram, Rachael Grazioplene, Jamila Hokanson, Anastasia Jankovsky, Stephen A Kichuk, Bradford Martins, Prerana Patel, Henry Schaer, Sarah Shnayder, Chelsea Witherow, Christopher Pittenger, Benjamin Kelmendi
Frontiers in Psychiatry February 16, 2024 correction DOI: 10.3389/fpsyt.2024.1372373 via OpenAlex
Summary
AI-generated from the abstractA correction notice addresses an error in a previously published article on psilocybin therapy for obsessive-compulsive disorder. The notice specifies that the original article's DOI is 10.3389/fpsyt.2023.1278823 and provides the necessary correction. No findings, methods, or results are presented in this text.
Study at a glance
| Characteristics | Randomized |
|---|---|
| Topics | Psilocybin |
| Keywords | Adult psychiatry Mental health Non-directive support Obsessive-compulsive disorder |
Abstract
[This corrects the article DOI: 10.3389/fpsyt.2023.1278823.].